Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0782
    -0.0012 (-0.11%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2627
    +0.0005 (+0.04%)
     
  • USD/JPY

    151.3320
    -0.0400 (-0.03%)
     
  • Bitcoin USD

    70,003.79
    -857.80 (-1.21%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,369.44
    +201.37 (+0.50%)
     

Cytek Biosciences Acquires Flow Cytometry & Imaging Business From DiaSorin

  • DiaSorin's subsidiary Luminex Corporation will sell its Flow Cytometry & Imaging (FCI) business unit to Cytek Biosciences Inc (NASDAQ: CTKB). Deal terms were not disclosed.

  • The FCI business unit, acquired by Luminex in October 2018, is based on conventional flow cytometry and image-based flow cytometry instrumentation, providing insights into all facets of cellular phenotypes and morphology.

  • The FCI business unit includes dedicated commercial, operations, R&D, and supporting personnel.

  • An existing installed base of more than 7,000 instruments will be under the Cytek umbrella following the acquisition, expanding the company's global commercial footprint.

  • The decision to sell the FCI business unit to Cytek aligns with the strategic priorities communicated to investors during the Capital Market Day in December 2021.

  • By adding first-to-market Amnis imaging flow cytometers to its robust lineup of cell analysis solutions, Cytek will be able to provide researchers and scientists with tools that combine high-resolution cell images with the speed, sensitivity, and phenotyping abilities of flow cytometry.

  • Adding Guava flow cytometers will expand Cytek's core instrument offerings, adding cost-effective, entry-level, and personal instrument options to broaden the market and research areas it services.

  • Price Action: CTKB shares closed at $13.00 on Monday.

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article Cytek Biosciences Acquires Flow Cytometry & Imaging Business From DiaSorin originally appeared on Benzinga.com

.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement